Evoke Wealth’s Vir Biotechnology VIR Stock Holding History

Evoke Wealth’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-41	Closed	-$1.41K	–	1198
2020 Q1	$1.41K	Buy	+41	New	+$1.1K	﹤0.01%	873

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Evoke Wealth's VIR Position: Q2 2020 in Review

Evoke Wealth sold out of Vir Biotechnology (VIR) in Q2 2020, closing a stake of 41 shares — an estimated $1.41K sold.

Evoke Wealth first reported a position in VIR in Q1 2020 and held it in 1 quarter. The position peaked at $1.41K in Q1 2020. 112 funds tracked by Wall St. Rank hold VIR as of Q2 2020.

Evoke Wealth reported no remaining Vir Biotechnology position as of Q2 2020 after selling out during the quarter.
Evoke Wealth sold 41 Vir Biotechnology shares in Q2 2020, an estimated $1.41K.
Evoke Wealth first reported a position in Vir Biotechnology in Q1 2020 and held it in 1 quarter.
Evoke Wealth's Vir Biotechnology position peaked at $1.41K in Q1 2020.
112 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2020.

Based on Evoke Wealth's 13F filing for Q2 2020, filed 10 Aug 2020.